Xperiome

Xperiome was a UK-based private healthtech company focused on rare diseases, using patient communities and real-world experience data to help biopharma companies understand patient journeys, improve study design, and recruit participants for clinical and real-world research. The company rebranded from Raremark to Xperiome in 2020 while retaining Raremark as its patient-facing brand. Its offering combined community-building, patient insight generation, and matching of research-ready patients to decentralized and conventional studies. Xperiome partnered with companies such as Science 37 to support faster and more patient-centric rare disease research. UK corporate records indicate that Xperiome Limited later entered liquidation, so the company does not appear to be an active operating business as of 2026.